Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 607137, 9 pages
http://dx.doi.org/10.1155/2013/607137
Clinical Study

Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody

1Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu-shi, Chiba 279-0021, Japan
2Department of Internal Medicine, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi, Chiba 279-0021, Japan
3Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
4Department of Rheumatology, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa-shi, Chiba 272-8516, Japan

Received 26 April 2013; Accepted 17 July 2013

Academic Editor: Vinod Chandran

Copyright © 2013 Mitsuaki Yanagida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Maini, M. J. Elliott, F. M. Brennan et al., “Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease,” Immunological Reviews, vol. 144, pp. 195–223, 1995. View at Google Scholar · View at Scopus
  2. J. Kempeni, “Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7,” Annals of the Rheumatic Diseases, vol. 58, supplement 1, pp. I70–I72, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. K. M. Mohler, D. S. Torrance, C. A. Smith et al., “Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists,” The Journal of Immunology, vol. 151, no. 3, pp. 1548–1561, 1993. View at Google Scholar · View at Scopus
  4. M. Mihara, N. Nishimoto, and Y. Ohsugi, “The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody,” Expert Opinion on Biological Therapy, vol. 5, no. 5, pp. 683–690, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Dall'Era and J. Davis, “CTLA4Ig: a novel inhibitor of costimulation,” Lupus, vol. 13, no. 5, pp. 372–376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Sekigawa, M. Yanagida, K. Iwabuchi et al., “Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis faetor-α antibody therapy,” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 261–267, 2008. View at Google Scholar · View at Scopus
  7. M. Yanagida, G. Jung, Y. Tanaka et al., “Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor,” International Journal of Rheumatic Diseases, vol. 15, no. 5, pp. 486–495, 2012. View at Publisher · View at Google Scholar
  8. K. Nozawa, M. Fujishiro, M. Kawasaki et al., “Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis,” Arthritis Research & Therapy, vol. 11, no. 6, article R174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Fujishiro, K. Nozawa, M. Kawasaki et al., “Regenerating gene (REG) 1 alpha promotes pannus progression in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 22, no. 2, pp. 228–237, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis & Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Google Scholar · View at Scopus
  11. O. Steinbrocker, C. H. Traeger, and R. C. Batterman, “Therapeutic criteria in rheumatoid arthritis,” Journal of the American Medical Association, vol. 140, no. 8, pp. 659–662, 1949. View at Google Scholar · View at Scopus
  12. M. L. L. Prevoo, M. A. van'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. van de Putte, and P. L. van Riel, “Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Tirumalai, K. C. Chan, D. A. Prieto, H. J. Issaq, T. P. Conrads, and T. D. Veenstra, “Characterization of the low molecular weight human serum proteome,” Molecular & Cellular Proteomics, vol. 2, no. 10, pp. 1096–1103, 2003. View at Google Scholar · View at Scopus
  14. N. L. Anderson and N. G. Anderson, “The human plasma proteome: history, character, and diagnostic prospects,” Molecular & Cellular Proteomics, vol. 1, no. 11, pp. 845–867, 2002. View at Google Scholar · View at Scopus
  15. J. Gauldie, C. Richards, D. Harnish, P. Lansdorp, and H. Baumann, “Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 20, pp. 7251–7255, 1987. View at Google Scholar · View at Scopus
  16. B. Cylwik, L. Chrostek, E. Gindzienska-Sieskiewicz, S. Sierakowski, and M. Szmitkowski, “Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis,” Advances in Medical Sciences, vol. 55, no. 1, pp. 80–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. M. Petersen, “Alpha 2-macroglobulin and pregnancy zone protein. Serum levels, alpha 2-macroglobulin receptors, cellular synthesis and aspects of function in relation to immunology,” Danish Medical Bulletin, vol. 40, no. 4, pp. 409–446, 1993. View at Google Scholar · View at Scopus
  18. C. H. W. Horne, A. W. Thomson, C. B. Hunter, A. M. Tunstall, C. M. Towler, and M. E. Billingham, “Pregnancy-associated α2-glycoprotein (α2-PAG) and various acute phase reactants in rheumatoid arthritis and osteoarthritis,” Biomedicine, vol. 30, no. 2, pp. 90–94, 1979. View at Google Scholar · View at Scopus
  19. S. Serada, M. Fujimoto, A. Ogata et al., “iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 69, no. 4, pp. 770–774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ajeganova, R. Fiskesund, U. de Faire, I. Hafström, and J. Frostegård, “Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis—a one-year study,” Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 942–950, 2011. View at Google Scholar · View at Scopus
  21. S. Y. Kawashiri, A. Kawakami, S. Yamasaki et al., “Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis,” Rheumatology International, vol. 31, no. 4, pp. 451–456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Soubrier, P. Jouanel, S. Mathieu et al., “Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis,” Joint Bone Spine, vol. 75, no. 1, pp. 22–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Nishimoto, Y. Kanakura, K. Aozasa et al., “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” Blood, vol. 106, no. 8, pp. 2627–2632, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Honkanen, Y. T. Konttinen, and H. Mussalo-Rauhamaa, “Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 7, no. 5, pp. 465–469, 1989. View at Google Scholar · View at Scopus
  25. T. Takeuchi, T. Kotani, T. Nakanishi, Y. Tabushi-Matsumura, T. Takubo, and S. Makino, “Proteomic analysis of changes in the serum protein profile by anti-TNF-alpha therapy,” Rinsho Byori, vol. 58, no. 4, pp. 332–336, 2010. View at Google Scholar · View at Scopus
  26. A. Ateş, G. Kinikli, M. Turgay, and M. Duman, “Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis,” Scandinavian Journal of Immunology, vol. 59, no. 3, pp. 315–320, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Ugur, K. Yildirim, A. Kiziltunc, A. Erdal, S. Karatay, and K. Senel, “Correlation between soluble intercellular adhesion molecule 1 level and extracellular superoxide dismutase activity in rheumatoid arthritis: a possible association with disease activity,” Scandinavian Journal of Rheumatology, vol. 33, no. 4, pp. 239–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Banerji, J. Ni, S.-X. Wang et al., “LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan,” The Journal of Cell Biology, vol. 144, no. 4, pp. 789–801, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Xu, J. Edwards, S. Banerji, R. Prevo, D. G. Jackson, and N. A. Athanasou, “Distribution of lymphatic vessels in normal and arthritic human synovial tissues,” Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1227–1229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Lehmann, B. Holzmann, E. W. Breitbart, P. Schmiegelow, G. Riethmuller, and J. P. Johnson, “Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000,” Cancer Research, vol. 47, no. 3, pp. 841–845, 1987. View at Google Scholar · View at Scopus
  31. J. M. Lehmann, G. Riethmuller, and J. P. Johnson, “MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 24, pp. 9891–9895, 1989. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Neidhart, R. Wehrli, P. Bruhlmann, B. A. Michel, R. E. Gay, and S. Gay, “Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 42, no. 4, pp. 622–630, 1999. View at Google Scholar
  33. P. K. Siiteri, J. T. Murai, G. L. Hammond, J. A. Nisker, W. J. Raymoure, and R. W. Kuhn, “The serum transport of steroid hormones,” Recent Progress in Hormone Research, vol. 38, pp. 457–510, 1982. View at Google Scholar · View at Scopus
  34. L. Mirone, L. Altomonte, P. D'Agostino, A. Zoli, A. Barini, and M. Magaró, “A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity,” Clinical Rheumatology, vol. 15, no. 1, pp. 15–19, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Simó, A. Barbosa-Desongles, C. Sáez-Lopez, A. Lecube, C. Hernandez, and D. M. Selva, “Molecular mechanism of TNFα-induced down-regulation of SHBG expression,” Molecular Endocrinology, vol. 26, no. 3, pp. 438–446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Haendler, J. Kratzschmar, F. Theuring, and W. D. Schleuning, “Transcripts for cysteine-rich secretory protein-1 (CRISP-1; DE/AEG) and the novel related CRISP-3 are expressed under androgen control in the mouse salivary gland,” Endocrinology, vol. 133, no. 1, pp. 192–198, 1993. View at Publisher · View at Google Scholar · View at Scopus
  37. F. R. Ribeiro, P. Paulo, V. L. Costa et al., “Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene,” PLoS ONE, vol. 6, no. 7, Article ID e22317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. R. H. Straub, P. Härle, F. Atzeni, C. Weidler, M. Cutolo, and P. Sarzi-Puttini, “Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy,” The Journal of Rheumatology, vol. 32, no. 7, pp. 1253–1258, 2005. View at Google Scholar · View at Scopus
  39. L. De Franceschi, S. Bosello, C. Scambi et al., “Proteome analysis of biological fluids from autoimmune-rheumatological disorders,” Proteomics Clinical Applications, vol. 5, no. 1-2, pp. 78–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Hueber, B. H. Tomooka, F. Batliwalla et al., “Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 11, no. 3, article R76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Nozawa, M. Fujishiro, M. Kawasaki et al., “Inhibition of connective tissue growth factor ameliorates rheumatoid arthritis in a murine model,” Arthritis & Rheumatism, vol. 65, no. 6, pp. 1477–1486, 2013. View at Publisher · View at Google Scholar